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Three specific β(1,3)glucan synthase (GS) 
inhibitor families -papulacandins, acidic 
terpenoids and echinocandins - have been 
analyzed in Schizosaccharomyces pombe wild-
type and papulacandin-resistant cells and GS 
activities. Papulacandin and enfumafungin 
produced similar in vivo effects, different to 
that of echinocandins. Also, papulacandin was 
the strongest in vitro GS inhibitor (IC50 103-
104-fold lower than with enfumafungin or 
pneumocandin), but caspofungin was by far 
the most efficient antifungal since it was 1) the 
only drug that affected resistant cells (MIC 
close to that of the wild-type); 2) a strong 
inhibitor of wild-type GS (IC50 close to that of 
papulacandin); and 3) the best inhibitor of 
mutant GS. Moreover, caspofungin showed a 
special effect for two GS inhibition activities, 
of high- and low-affinity, separated by two 
log-orders, with no increase in inhibition. 
pbr1-8 and pbr1-6 resistances are due to single 
substitutions in the essential Bgs4 GS, located 
close to the resistance hot spot 1 region 
described in Saccharomyces and Candida Fks 
mutants. Bgs4pbr1-8 contains the E700V change, 
four residues N-terminal from hot spot 1 
defining a larger resistance hot spot 1-1 of 13 
amino acids. Bgs4pbr1-6 contains the W760S 
substitution, defining a new resistance hot 
spot 1-2. We observed spontaneous revertants 
of the spherical pbr1-6 phenotype and found 
that an additional A914V change is involved 
in the recovery of the wild-type cell shape but 
maintaining the resistance phenotype. A 
better understanding of the mechanism of 
action of the antifungals available should help 
to improve their activity and to identify new 
antifungal targets. 
 
 
 
 
The number of antifungal families available 
and their use in therapy is very limited (1-4). 
Recently, a new family of specific fungal cell 
wall synthesis inhibitors has emerged as an 
alternative antifungal therapy and is gaining 
increasing relevance yearly (5-7). 
The cell wall is a structure external to the 
plasma membrane and is present in all fungal 
cells. Its integrity is crucial and it constitutes the 
exoskeleton that confers mechanical strength and 
osmotic resistance to fungal cells (8-10). In 
mammalian cells, the cell wall is absent and 
consequently drugs that interfere with its 
synthesis are attractive as potential antifungal 
agents. β(1,3)glucan is a major contributor to the 
framework of the cell wall. There are several 
families of antifungal drugs whose mode of 
action is not well known, although they clearly 
interfere with β(1,3)glucan synthesis by 
inhibiting the β(1,3)glucan synthase (GS) 
enzyme. These inhibitors include echinocandins 
(lipopeptides), papulacandins (glycolipids) and 
acidic terpenoids such as enfumafungin (2,11). 
To date, only the echinocandins caspofungin, 
micafungin and anidulafungin have been 
approved (in years 2002, 2005 and 2006, 
respectively) for treatment of invasive fungal 
infections (1,3,5,7,12). 
The fission yeast Schizosaccharomyces 
pombe provides an appealing model for studies 
addressing cell wall synthesis and 
morphogenesis. The S. pombe cell wall has no 
detectable chitin (10) but it contains three 
different essential β-glucans: a branched 
β(1,3)glucan, which  is the major contributor to 
the cell wall structure; a minor linear 
β(1,3)glucan, concentrated in the primary 
septum, with minor amounts in the cell wall, and 
a minor branched β(1,6)glucan (13,14). S. pombe 
contains four essential putative GS catalytic 
subunits: Bgs1 to Bgs4. Bgs1 is responsible for 
the synthesis of the linear β(1,3)glucan and 
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primary septum. Bgs2 is essential for spore wall 
maturation, and Bgs3 is essential, although its 
function remains unknown. Bgs4 is the only 
subunit that has been shown to form part of the 
GS enzyme. It is responsible for the major part of 
cell wall β(1,3)glucan synthesis and in vitro GS 
activity, and it is essential for the maintenance of 
cell integrity during cell growth and separation 
(14-17). The different essential functions of Bgs 
proteins in cell morphogenesis make them good 
targets for the study of antifungal drugs that 
specifically inhibit β(1,3)glucan synthesis. 
The S. pombe Bgs family is homologous to 
fungal Fks and plant CalS proteins, considered to 
be putative GS catalytic subunits (8,18). Fungal 
resistance to GS inhibitors is clearly associated 
with mutations in conserved short regions (hot 
spots) of the Fks proteins, indicating that this 
mechanism is well conserved in fungi (12,19,20). 
In addition, intrinsic echinocandin-resistant fungi 
contain natural substitutions in the conserved Fks 
region that are determinants of their resistance 
(19,21-23). Most of the mutants resistant to GS 
inhibitors have been isolated as resistant to 
echinocandins. Only some Saccharomyces 
cerevisiae and S. pombe mutants have been 
selected as resistant to papulacandin (24,25), in 
each case defining a single complementation 
group called pbr1. However, whereas the S. 
cerevisiae pbr1-1 mutation has been associated 
with FKS1, the S. pombe pbr1+ gene remains 
unknown. 
In light of the above data, we were prompted 
to study and compare the mechanism of action of 
the three antifungal families: papulacandins, 
acidic terpenoids and echinocandins. Using S. 
pombe as a model, we examined the in vivo and 
in vitro effect of the antifungals on cells and the 
GS of wild-type and resistant mutants. Our data 
point to important differences among the 
antifungal families in both cells and GS activity. 
Caspofungin was overall the best inhibitor of 
cells and GS tested, not only of the wild type but 
also resistant cells. Although S. pombe vegetative 
cells contain three essential Bgs subunits, the 
antifungal resistance is exclusively associated 
with Bgs4, suggesting that Bgs1 and Bgs3 are 
intrinsic resistant subunits. Papulacandin 
selection afforded two new amino acid 
substitutions, expanding the resistance hot spot 1 
to 13 residues and defining a new resistance hot 
spot 1-2. These new sites, which are important 
for resistance and interaction with antifungals, 
should help to understand the mechanism of 
action of antifungals and the resistance 
mechanism of the Bgs / Fks proteins. 
 
EXPERIMENTAL PROCEDURES 
 
Strains and culture conditions. The S. pombe 
strains used were isogenic to wild-type strain h- 
972. The pbr1-1, pbr1-2, pbr1-3, pbr1-6 and 
pbr1-8 mutants were obtained by ethyl 
methanesulfonate mutagenesis (15-30 % 
survival) and selection in the presence of 20 
µg/ml of papulacandin B (25). The five mutants 
were backcrossed three times with the wild-type 
strain. In all the cases, tetrad analysis revealed a 
2R:2S segregation, indicating the monogenic 
trait or the resistance phenotype. The dominant / 
recessive analysis was performed in stable 
heterozygous diploid strains, using the mat2P-
B102 mutation (26). All the papulacandin 
resistance mutations proved to be recessive. 
Complementation analysis was carried out in 
diploid strains and showed that the five 
resistance mutations are alleles of the same gene, 
which was named pbr1 (from papulacandin B 
resistant). 
The standard complete yeast growth medium 
(YES), selective medium (EMM) supplemented 
with the appropriate amino acids and sporulation 
medium (SPA) (26,27) have been described 
previously. Cell growth was monitored by 
measuring the A600 of early log-phase cell 
cultures in a Coleman Junior II 
spectrophotometer (OD600 0.1 = 1x107 cells/ml). 
The general procedures for yeast and bacterial 
culture and genetic manipulations were carried 
out as described (27,28). 
Plasmids and DNA techniques. The multicopy 
pAL-bgs4+ (S. cerevisiae LEU2 selection) and 
integrative single copy pJK-bgs4+ plasmids (S. 
pombe leu1+ selection) have been described 
elsewhere (15). All the bgs4+ plasmids contain 
an 8.84 kb PstI-NheI bgs4+ fragment. The 
integrative phis3-bgs4+ plasmid (his3+ selection) 
contains the Bluescript KS+ backbone, the 2.3 kb 
Eco47III-DraI his3+ sequence cloned into 
EcoRV (KpnI-SacI orientation), and the bgs4+ 
sequence from pAL-bgs4+ cloned into PstI-NotI. 
p81X-bgs4+ is pJR2-81XL (LEU2 selection and 
81X version of the thiamine-repressible nmt1+ 
promoter) (29) containing the bgs4+ ORF (15). 
pAL-bgs4pbr1-8 contained bgs4pbr1-8 obtained 
from the pbr1-8 strain by plasmid gap-repair. 
pAL-bgs4+ was digested with SacI (removing the 
bgs4+ ORF, 680 bp of promoter and 188 bp of 
terminator), transferred into strain pbr1-8, and 
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repaired pAL-bgs4pbr1-8 plasmids were recovered 
from transformants. Integrative pJK-bgs4pbr1-8 
and phis3-bgs4pbr1-8 and regulatable p81X-
bgs4pbr1-8 contained bgs4pbr1-8 from pAL-bgs4pbr1-
8. The 8.8 kb region of bgs4pbr1-8 contained a 
single base substitution, A2099T, resulting in the 
E700V amino acid change of Bgs4,  and bgs4pbr1-
6 contained the single G2279C base substitution, 
resulting in the W760S amino acid change of 
Bgs4 (see results). 
bgs4pbr1-8 gene deletion was performed in a 
pbr1-8 / pbr1-8 diploid by removing the entire 
ORF of a bgs4pbr1-8 copy, as described for bgs4+ 
gene deletion (15). Bgs4 is essential and 
therefore haploid bgs4pbr1-8Δ deletion strains 
were maintained viable with a plasmid 
expressing bgs4+. 
Antifungal drugs and resistance assays. The 
antifungals were generous gifts from Ciba-Geigy 
/ Novartis (papulacandin B), Tokyo Jozo 
(aculeacin A) and Merck, Sharp and Dohme 
(enfumafungin, pneumocandin B0 and 
caspofungin). The antifungals were kept at -20ºC 
in stock solution (10 mg/ml in DMSO, except 
caspofungin, which is highly soluble in water) 
and assayed at the final concentrations specified 
in the text and figures. 
For micro-culture assays of large numbers of 
samples, late log-phase cultures grown in YES 
medium were diluted to a cell density of 2 x 106 
cells/ml in 200 µl of YES medium containing 
increasing concentrations of antifungal (0, 1, 2, 
5, 10, 20, 50 and 100 µg/ml) or an equivalent 
volume of solvent. The cell cultures were 
incubated in an orbital roller at 28ºC and 
turbidity was analyzed after 24 and 48 h of 
incubation, affording values ranging from 0 (-, 
no turbidity, wild-type cells in the presence of a 
lethal concentration of antifungal) to 100 (+++, 
total turbidity, wild-type cells in the absence of 
antifungal). The MIC (Minimal Inhibitory 
Concentration) was determined as the minimal 
concentration of antifungal that produced 
complete cell growth inhibition after 24 h of 
incubation. The values were calculated from at 
least three independent experiments. 
Enzyme preparation and β(1,3)glucan synthase 
(GS) assay. Cell extracts and GS assays were 
performed essentially as described (30). Cell 
extracts were obtained from early log-phase cells 
grown in YES medium at 28ºC. The cells were 
washed with buffer A (50 mM Tris-HCl pH 7.5, 
1 mM EDTA and 1 mM β-mercaptoethanol), 
suspended in 100 μl of buffer A containing 50 
µM GTPγS to preserve enzyme activity, and 
broken with glass beads. Membrane enzyme 
extracts were resuspended in the same buffer 
containing 33% glycerol and 50 µM GTPγS and 
stored at -80ºC. All GS assays (150 µM GTPγS 
and 15-25 μg of protein) were carried out in 
duplicate and the values were calculated from at 
least three independent cell cultures. 
Other procedures. The fractionation of cell wall 
polysaccharides, enzymatic lysis of cell 
suspensions (31), and fluorescence microscopy 
of cell walls stained with Calcofluor White (30), 
have been described previously.  
 
RESULTS 
 
The pbr1 mutants present increasing cell-
wall related phenotypes. The isolation of S. 
pombe mutants resistant to papulacandin B, 
which defined a single complementation group 
designated pbr1 (for papulacandin B resistant), 
has been reported previously (25). pbr1-6 cells 
show a special spherical morphology (Fig. 1), 
which has been associated with a single recessive 
gene called sph1-1 (24). This mutant was 
characterized as being defective in cell wall 
galactomannan, which could account for a cell 
integrity defect responsible for the spherical 
phenotype. In fact, osmotic stabilization with 
sorbitol suppressed that phenotype (Fig. 1A). 
However, the morphology of the other pbr1 
alleles was that of both normal and lemon-
shaped cells (Fig. 1A and data not shown). This 
led us to consider the possibility that both 
phenotypes might be related, pbr1-6 being the 
result of a more aggravated phenotype. 
Accordingly, the cell-wall related phenotypes of 
pbr1-6 and pbr1-8 (the latter being representative 
of the other mutant alleles) were examined 
(Table 1).  
The fluorochrome Calcofluor White 
specifically binds to growing poles, and with 
especially high affinity for the septum (14). 
pbr1-8 and pbr1-6 cells showed increasing 
Calcofluor staining, which was more intense in 
pbr1-6 cells, where the compound stained the 
whole cell wall and the septa appeared thicker 
and more strongly stained (Fig. 1A). Cell wall 
analyses also revealed increasing phenotypes: 
from the wild-type to pbr1-8, to pbr1-6 (Table 
1). With mild alkali extraction of the cell walls a 
gradual increase in susceptibility was observed. 
Lysis of cell suspensions with Novozyme also 
elicited increasing susceptibility. By contrast, the 
mutant cells exhibited increasing resistance to 
Zymolyase degradation. Novozyme degrades the 
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cell wall, suggesting an increasing defect in cell 
wall structure and integrity. However, 
Zymolyase does not contain α-glucanases and 
hence resistance to degradation indicates a 
progressive increase in cell wall α-glucan levels. 
This was confirmed by cell wall fractionation, 
which revealed a gradual increase in total cell 
wall, β-glucan and α-glucan, and a gradual 
decrease in galactomannan. Similarly, the 
amount of cell wall hexoses changed: glucose 
increased whereas mannose and galactose 
decreased (Table 1). 
The above findings indicate that both pbr1-8 
and pbr1-6 mutants show similar cell-wall-
related phenotypes, more aggravated in pbr1-6. 
However, although the mutants were selected as 
being resistant to a β(1,3)glucan synthase (GS) 
inhibitor, the kinetic parameters of in vitro 
mutant GS activities (specific activity, Km and 
Vmax) were not altered either in the absence 
(24,25) or in the presence of papulacandin (50 
μg/ml, data not shown). 
Differential in vivo effect of three families of 
specific β(1,3)glucan synthase (GS) inhibitors on 
wild-type and resistant stains. The pbr1 mutants 
were obtained as being resistant to papulacandin 
B and also showed resistance to aculeacin A. 
However, pbr1-6 was again different since it 
showed normal sensitivity to aculeacin A. Owing 
to the different behavior of the pbr1-6 and pbr1-
8 mutants with aculeacin A and to the fact that 
only a few antifungals have been analyzed, 
antifungals representative of the different 
families of specific GS inhibitors (2) were 
selected to study their in vivo and in vitro effects 
on wild-type and resistant strains and GS 
activities: papulacandin B (papulacandins), 
enfumafungin (acidic terpenoids), aculeacin A, 
pneumocandin B0 and caspofungin 
(echinocandins) (Fig. 2). 
First, a different in vivo inhibitory capacity 
was observed, depending on the antifungal 
family. In wild-type cells, papulacandin and 
enfumafungin produced a dramatic and complete 
arrest of cell growth, whereas the echinocandins 
permitted residual cell growth even at higher 
concentrations (Fig. 3A). This was accompanied 
by a different lytic effect. Papulacandin and 
enfumafungin led to rapid and total cell lysis 
whereas the echinocandins produced lysed cells 
accompanied by swollen, round and aberrant 
cells (data not shown). Similar two-type 
antifungal effects were also observed with the 
pbr1-8 and pbr1-6 resistances; complete 
resistance and an unaltered morphology with 
papulacandin and enfumafungin, and weaker 
resistance and cells becoming round and 
aggregated with the echinocandins (Fig. 3A,B) or 
even no resistance at all, as in the case of pbr1-6 
strain with aculeacin (Fig. 3B). 
The MIC of the three antifungal families was 
similar in the wild-type strain (5-10 µg/ml, Table 
2) and again defined two antifungal groups in the 
resistant strains: highly resistant with 
papulacandin and enfumafungin, and less 
resistant with the echinocandins (Table 2). Like 
aculeacin, the other echinocandins also elicited 
differences between the resistant strains, pbr1-8 
exhibiting higher resistance than pbr1-6 (Table 
2). 
Differential in vitro effect of three families of 
specific GS inhibitors on wild-type and resistant 
GS activities. Owing to the different effects 
observed in vivo with the antifungals analyzed 
and to the fact that all these antifungals are 
specific GS inhibitors, the effect of the three 
inhibitor families on the in vitro GS activity of 
the wild-type strain was analyzed (Fig. 4A). 
Enfumafungin and pneumocandin showed 
similar IC50 (half-maximal inhibitory 
concentration) values. Surprisingly, 
papulacandin showed a very strong GS inhibitory 
activity, with an IC50 103-104-fold lower than that 
of enfumafungin and pneumocandin (Fig. 4A 
and Table 2). 
Accordingly, the pbr1-6 and pbr1-8 mutants 
were analyzed for their in vitro GS resistance to 
the three antifungals (Fig. 4B and Table 2), and 
the results were compared to the data previously 
reported for aculeacin (25). Both mutant GS 
showed high resistance to all the antifungals, 
with an IC50 above 250 µg/ml even in the case of 
pbr1-6 GS with aculeacin. However, some 
differences were observed between both mutant 
GS (Fig. 4B): 1) pbr1-8 GS showed higher 
resistance to the inhibitors than pbr1-6 GS, 
which at least correlates with the lower 
resistance to the echinocandins of the pbr1-6 
cells; 2) enfumafungin and pneumocandin 
promoted a specific activation of pbr1-8 (110-
120%) but not of pbr1-6 GS activity; 3) pbr1-8 
GS resistance to papulacandin remained above 
that of pbr1-6 across the range analyzed, whereas 
with enfumafungin and pneumocandin it 
decreased faster, lower resistance being observed 
at high drug concentrations. These results show 
that 1) each antifungal family produces a 
different effect on wild-type and mutant GS 
activities; 2) each mutant GS exhibits a different 
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resistance pattern, depending on the inhibitor 
analyzed. 
Novel and special effect of caspofungin on in 
vitro wild-type and resistant GS activities. 
Owing to its clinical relevance, the effect of the 
echinocandin derivative caspofungin on wild-
type GS activity was analyzed (Fig. 4C and 
Table 2). Caspofungin proved to be a potent GS 
inhibitor, with an interesting novel effect on its 
activity. First, the compound showed strong GS 
inhibitory activity, with an IC50 102-103-fold 
lower than that of the antifungals tested, except 
papulacandin (IC50 still 10-fold lower). Second, 
caspofungin promoted two GS inhibition levels: 
a high-affinity inhibition, with a gradual decrease 
in GS levels down to 40% activity, and a low-
affinity inhibition, with a new decrease in GS 
activity until complete inhibition. Both inhibition 
ranges were separated by a plateau of two orders 
of magnitude in which increasing caspofungin 
did not produce any additional inhibitory effect 
(Fig. 4C). 
As observed with other antifungals, pbr1-8 
GS was more resistant to caspofungin than pbr1-
6 GS and showed a constant activation (110%) 
over a broad concentration range of inhibitor 
(Fig. 4D). pbr1-8 GS proved to be resistant to the 
high-affinity inhibition but sensitive to the low-
affinity inhibition. pbr1-6 GS showed lower 
resistance, with partial inhibition in the high-
affinity inhibition range, remaining constant 
during the plateau of two log orders of 
caspofungin. Increasing concentrations of 
caspofungin elicited a complete inhibition, 
similar to the wild-type inhibition. This indicates 
that pbr1-8 and pbr1-6 GS are only resistant to 
the high-affinity inhibition effect of caspofungin. 
In addition, caspofungin was a potent inhibitor of 
mutant GS since it was the only drug that 
produced measurable IC50 values, which were 
lower in pbr1-6 than in pbr1-8 GS (150 and 250 
μg/ml, respectively; Fig. 4D and Table 2). 
bgs4+ is unable to suppress the pbr1-8 
resistance phenotype. Previously, pbr1-8 has 
been genetically linked to cwg1-1. Both are GS-
related genes, suggesting that pbr1+ and cwg1+ 
could be the same gene. pbr1-8 resistance is 
recessive, but cloning of the pbr1+ gene has been 
unsuccessful, as is the case of cwg1+ (25,32). 
Cloning from a cosmid clone of the bgs4+ gene 
of the essential GS subunit revealed that bgs4+ is 
allelic to cwg1+ (15). 
The above results also suggested that pbr1+ 
and bgs4+ could be the same gene. The fact that 
in S. cerevisiae and other fungi the resistance to 
GS antifungals is due to mutations in the Fks GS 
homologues (12,19,25,33-36) supports the idea 
that specific bgs4 mutations could be responsible 
for the resistance phenotypes. To test this notion, 
the resistance phenotypes of pbr1-8 and pbr1-6 
mutants expressing bgs4+ (own promoter, 
multicopy and single-copy integrative plasmids) 
were analyzed. pbr1-8 and pbr1-6 resistances are 
recessive (25) (see below: Fig. 6B and Table 3). 
However, bgs4+ was unable to suppress the 
papulacandin, enfumafungin and pneumocandin 
resistances of pbr1-8, although it did suppress 
the resistance to caspofungin (Fig. 5A and Table 
3). This was not the case with pbr1-6, in which 
suppression of all the resistances by bgs4+ was 
observed (Fig. 5B and Table 3), as would be 
expected if pbr1+ and bgs4+ were the same gene. 
A similar absence of pbr1-8 suppression by 
bgs4+ was observed in the in vitro GS resistance 
of pbr1-8 cells expressing bgs4+ (Fig. 5C). This 
effect was not due to a defective pbgs4+ since no 
changes were found in the 8.8 kb bgs4+ sequence 
and pbgs4+ was able to suppress the phenotype 
of other bgs4 mutants (15). 
In order to study whether pbr1-8 resistance 
was related to bgs4+, bgs4 from the pbr1-8 strain 
(bgs4pbr1-8) was cloned and analyzed. pbgs4pbr1-8 
did not confer resistance to a wild-type strain, as 
expected for a recessive mutation, but it did 
provide resistance to a bgs4Δ strain (Fig. 6A). 
Similarly, a heterozygous WT / pbr1-8 diploid 
was sensitive but bgs4Δ / pbr1-8 showed 
resistance to the GS inhibitors (Fig. 6B and 
Table 5). Contrary to the incapacity of bgs4+ to 
suppress the haploid pbr1-8 resistance, bgs4+ 
was able to suppress the bgs4Δ / pbr1-8 
resistance. When a regulatable promoter was 
used, the bgs4Δ / pbr1-8 strain showed resistance 
when bgs4+ expression was repressed and the 
sensitive phenotype when bgs4+ was induced 
(Fig. 6C). This suggested that bgs4pbr1-8 is 
responsible for at least part of the resistance of 
pbr1-8. 
Sequencing of the bgs4 ORF and adjacent 
regions of the pbr1 mutant alleles revealed the 
substitution of only one base in the 8.8 kb DNA 
sequence of each mutant. pbr1-8 and the rest of 
the alleles, except pbr1-6, contained the same 
A2099T substitution, resulting in the E700V 
amino acid change. pbr1-6 contained the 
G2279C substitution, encoding the W760S 
amino acid change; 60 amino acids C-terminal 
from the pbr1-8 mutation. Both residues -E700 
and W760- are very well conserved and are 
located in the predicted first transmembrane 
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region of the Bgs / Fks / CalS protein family 
(Fig. 7A). Interestingly, the  Bgs4pbr1-8 mutation 
is close to a conserved 9-amino-acid resistance 
hot spot 1 described from the Fks sequences of 
Saccharomyces and Candida species, whose 
mutations confer resistance to echinocandins 
(Fig. 7B) (12,21,22,37-43). The Bgs4pbr1-8 
mutation permitted a larger 13-amino-acid hot 
spot 1-1 to be defined. In addition, the Bgspbr1-6 
mutation was located in a new resistance site, C-
terminal from the hot spot 1-1, defining a new 
hot spot 1-2 of resistance to papulacandins, 
enfumafungin and echinocandins (Fig. 7B).  
To confirm that the Bgs4 E700V and W760S 
mutations were responsible for the pbr1-8 and 
pbr1-6 resistances, plasmids with the 
corresponding bgs4 substitution were made by 
site-directed mutagenesis and analyzed in a 
bgs4Δ strain. The Bgs4pbr1-8 and Bgs4pbr1-6 
protein levels were similar to that of Bgs4 (data 
not shown). Both bgs4 mutants conferred the 
same resistances as those of the pbr1-8 and pbr1-
6 strains. In addition, bgs4pbr1-6 generated a 
spherical phenotype similar to that of the sph1-1 
mutant (Fig. 1A), indicating that sph1+ is also 
allelic to bgs4+ and that both sph1-1 and pbr1-6 
phenotypes are due to the single W760S 
mutation. The spherical pbr1-6 (sph1-1) 
phenotype was unstable, originating spontaneous 
morphological revertants with an elongated cell 
shape and faster growth. Sequencing of the  
bgs4pbr1-6 revertants revealed the initial W760S 
mutation and a spontaneous A914V suppressor 
mutation (C2741T base change) (Fig. 1B). The 
suppressor function of A914V was confirmed by 
inserting this mutation into pbgs4pbr1-6 and 
observing a similar suppression (Fig. 1B). 
However, the antifungal resistance was not 
affected (Table 3), indicating that the A914V 
suppressor is specific to the pbr1-6 
morphological and cell integrity defects. 
Genetic study of the absence of pbr1-8 
suppression by bgs4+. The fact that the resistance 
of the haploid pbr1-8 strain was not suppressed 
but the resistance of the pbr1-8 / bgs4Δ strain 
was suppressed by bgs4+ suggested the 
possibility of a second recessive resistance 
mutation. This second resistance should be 
linked to bgs4pbr1-8 since the resistance 
segregated 2R:2S in genetic crosses. 
To test this, larger DNA fragments 
containing bgs4+ and adjacent ORFs were 
cloned. None of the fragments suppressed the 
pbr1-8 phenotype but they did suppress that of 
cwg1-1. In ensuing experiments, total or partial 
5´ or 3´-end deletions or simple deletion of the 
ATG start codon of bgs4pbr1-8 ORF suppressed 
both bgs4pbr1-8 function and antifungal resistance. 
These results therefore indicate that pbr1-8 
resistance is only due to the bgs4pbr1-8 mutation. 
The expression level of bgs4+ determines its 
capacity to suppress the pbr1-8 resistance 
phenotype. In order to study the unexpected 
effect of the absence of pbr1-8 resistance 
suppression by bgs4+, a protocol for micro-
culture assays was developed. As before, 
heterozygous WT / pbr1-8 showed the recessive 
resistance trait and pbgs4+ was unable to 
suppress the haploid pbr1-8 or diploid pbr1-8 / 
pbr1-8 resistances, except to caspofungin (Table 
3). The pbr1-6 strain showed resistance to the 
four drugs and in this case bgs4+ was able to 
suppress the four resistances (Table 3). 
However, when the wild-type bgs4+ and 
mutant bgs4pbr1-8 plasmids were expressed in the 
same cell, either haploid or diploid, in the 
absence of endogenous bgs4 gene pbgs4+ was 
able to suppress the resistance due to pbgs4pbr1-8 
(Table 4). Therefore, bgs4+ expressed from a 
plasmid is unable to suppress the endogenous 
pbr1-8 resistance but is able to suppress a similar 
resistance conferred by the bgs4pbr1-8 plasmid. 
The absence of pbr1-8 suppression by 
pbgs4+ was opposite to the suppression observed 
with p81X-bgs4+ (Fig. 6C). To study this 
discrepancy, p81X-bgs4+ was analyzed in the 
pbr1-8 and pbr1-8 / pbr1-8 strains that had 
previously showed an absence of suppression by 
pbgs4+ (Table 3). Surprisingly, induced p81X-
bgs4+ was able to suppress the resistance of both 
strains (Table 5). This suggests that the ability of 
bgs4+ to suppress the pbr1-8 resistance depends 
on the expression level of the corresponding 
bgs4+ plasmid. This was confirmed by 
expressing pbgs4+ in hemi-dosage pbr1-8 / 
bgs4Δ diploid cells. Whereas pbgs4+ did not 
suppress pbr1-8 / pbr1-8 resistance (Table 3), it 
did suppress pbr1-8 / bgs4Δ resistance (Table 5). 
This shows that the ectopic gene expression may 
be less efficient than the chromosomal gene 
expression, sufficient to suppress some (cwg1-1, 
cwg1-2, orb11-56, pbr1-6) but not other 
mutations (pbr1-8). 
 
DISCUSSION 
 
S. pombe is an attractive model to study the 
effect of antifungals specific to β(1,3)glucan 
synthesis. Its special rod shape makes the fission 
yeast an excellent organism to explore 
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morphological defects. Any minor cell wall 
defect will result in detectable morphological 
changes. In addition, S. pombe has no detectable 
chitin and therefore β(1,3)glucan acquires more 
relevance as a structural cell wall polysaccharide. 
Most fungi contain a single essential Fks protein 
or two redundant Fks subunits, which are only 
essential when both are affected. In this sense, S. 
pombe is also special since it contains four Fks 
homologs, Bgs1 to Bgs4, and three of them -
Bgs1, Bgs3 and Bgs4- are essential for 
vegetative cells. Therefore, study of the effect of 
GS inhibitors on S. pombe cells, GS activity, and 
Bgs subunits could provide important 
information about the mechanism of action of 
each family of specific GS inhibitors.  
Analysis of the resistance of fission yeast to 
GS inhibitors could also provide interesting 
information. Resistance to GS inhibitors in other 
fungi is associated with mutations in their single 
Fks protein. In the case of S. pombe, a mutation 
in only one of the three essential Bgs proteins 
would not alter the antifungal sensitivity of the 
two other Bgs subunits and the cell would remain 
sensitive to the antifungals. Therefore, which 
mechanism confers antifungal resistance to S. 
pombe cells? Initially, one possibility was that 
the resistance was due to a general regulator of 
the three Bgs proteins. However, cloning of the 
gene involved in the resistance revealed that it 
was exclusively associated with Bgs4, implying 
that Bgs1 and Bgs3 are not affected by the 
antifungals. This opens interesting new questions 
about the intrinsic resistance of Bgs1 and Bgs3, 
even though their sequences harbor all the 
residues that are determinant for the Bgs4 / Fks 
sensitivity to GS antifungals. The identification 
of Bgs1 and Bgs3 as new antifungal targets 
opens new possibilities in the search for new GS 
inhibitors with a broader mechanism of action. 
There are several antifungal families that 
specifically inhibit β(1,3)glucan synthesis and 
GS activity (2,12,44,45), but little is known 
about their mechanisms of action. In this work, 
we compared the effect of three GS inhibitor 
families on S. pombe wild-type and 
papulacandin-resistant cells and GS activities, 
and we found interesting differences both in vivo 
and in vitro. In wild-type cells, papulacandin and 
enfumafungin cause generalized cell lysis, 
mainly during cell separation (our unpublished 
results) and subsequent total cell growth arrest, 
whereas resistant cells are not affected. 
Echinocandins are different; the lysis of wild-
type cells is incomplete and the surviving cells 
become rounded and maintain a residual cell 
growth. The resistant cells are partially affected 
in morphology and cell growth and their 
resistance is variable, depending on the type of 
mutant and echinocandin, ranging from high 
(pbr1-8 with pneumocandin), to low 
(caspofungin), to non-resistant (pbr1-6 with 
aculeacin). This effect could be due to a distinct 
permeability to the different drugs, but in that 
case the cell should present similar or higher 
resistance than its in vitro GS resistance, and in 
our case we observed the opposite. It should be 
noted that whereas pbr1-8 and pbr1-6 were 
highly resistant to papulacandin and 
enfumafungin, they exhibited the opposite 
behavior with respect to aculeacin; pbr1-8 was 
highly resistant and pbr1-6 was sensitive. The 
finding of this variability in the resistance to 
echinocandins was possible because the mutants 
were selected for their resistance to papulacandin 
(25). Most of the mutants described have been 
isolated as resistant to echinocandins 
(12,21,22,37-43).  We have inserted some of 
these mutations into bgs4+, and none of them 
altered the in vivo sensitivity of the cells to 
papulacandin and enfumafungin, but produced 
variable degrees of resistance to echinocandins 
(our unpublished results), showing that each 
antifungal family acts through different sites of 
the GS enzyme and that some resistances may be 
specific to a given antifungal family. We have 
also analyzed the GS inhibitor Aerothricin3 / 
FR901469 (generous gift from Dr. Osamu 
Kondoh, Chugai Pharmaceutical) (46) on wild-
type and resistant cells and we found no 
differences. GS antifungals such as Aerothricin3, 
acting on different sites of the Bgs4 / Fks 
proteins, could be good candidates for a 
combined therapy to minimize the appearance of 
resistant strains. 
The MIC values of papulacandin and 
aculeacin described for S. cerevisiae and 
Candida are similar to the values for S. pombe 
(11,25,47,48). In other cases, the MIC value of a 
specific inhibitor fluctuate, depending on the 
method of analysis, the strain, or the organism. 
The MIC values of caspofungin described for C. 
albicans (0.0125-0.8 µg/ml) and other Candida 
species (0.01-8.0 µg/ml) are highly variable, 
although overall they denote a lower MIC 
compared to that obtained for S. pombe 
(11,23,49). This could be due to a lower 
susceptibility of Bgs4 or to a compensatory 
mechanism of the intrinsic resistant Bgs1 and 
Bgs3 subunits. 
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We compared the in vitro effect of each 
antifungal family on wild-type GS activity. 
Papulacandin exerted an in vitro effect that was 
103-104-fold stronger than that of the other drugs, 
except caspofungin. This effect has not been 
described in previous studies (25), probably due 
to the method used to prepare the GS enzyme. 
However, this in vitro difference was not 
correlated with a similar increase in in vivo 
susceptibility. This could be due to other 
antifungal interactions with the cell or to the in 
vivo accessibility of the enzyme. A similar case 
was observed with caspofungin, with an IC50 102-
103-fold lower than that of the other drugs, 
except papulacandin, with no correlation with its 
in vivo inhibitory capacity. By contrast, some in 
vitro mutant GS resistances to pneumocandin, 
aculeacin or caspofungin are much higher than 
the resistances detected in the cells. Furthermore, 
some bgs4 mutants are not resistant in vivo but 
do show in vitro GS resistance to echinocandins 
(our unpublished results). These differences 
show that in vitro GS resistance may be 
insufficient to confer resistance to cells, and 
suggest the presence of other targets modulating 
the GS activity in vivo. 
Interestingly, we observed that some of the 
antifungals tested were able to increase the 
mutant GS activity above the initial activity. This 
activating effect was observed in pbr1-8 but not 
in pbr1-6 GS activity, denoting specific and 
antagonistic drug effects that depend on the 
interacting GS conformation. pbr1-8 is activated 
by enfumafungin and echinocandins but other 
bgs4 mutants are also activated by papulacandins 
or only one antifungal (our unpublished results). 
No GS activation by GS inhibitors has been 
reported, except for papulacandin (50). In that 
case, the drug activation affected the wild-type 
GS and was dependent on low substrate 
concentrations. It is possible that some 
mutations, such as that of pbr1-8, in the presence 
of an antifungal could mimic the proposed 
preferential binding of substrate to the active 
form of the enzyme. 
Among the inhibitors studied, caspofungin 
was seen to be the best candidate for antifungal 
therapy. The caspofungin MIC of resistant 
strains was much lower than that of the other 
drugs and it produced a reduction in cell growth 
and an altered morphology of resistant cells. 
Caspofungin also showed special properties as 
regards the in vitro GS activity, with an IC50 102-
103-fold lower than that of other drugs, except 
papulacandin, and with two hitherto unreported 
inhibitory effects of high- (<0.7 μg/ml) and low- 
(>70 μg/ml) affinity. This suggests the presence 
of two GS interaction sites with caspofungin. 
Both pbr1-8 and pbr1-6 GS were resistant to the 
high-affinity inhibition but not to the low-affinity 
inhibition, suggesting that the resistance hot 
spots 1-1 and 1-2 would be located in the region 
involved in this high-affinity interaction with 
caspofungin. One candidate for the low-affinity 
interaction site could be a short hot spot 2 
located in the predicted second transmembrane 
region (12,41). Alternatively, the low-affinity 
inhibition could be due to interactions between 
caspofungin and Bgs1 or Bgs3. Both hypotheses 
are currently under investigation. 
The interesting effect of caspofungin in that 
it produces two separate inhibitory effects is 
different from the paradoxical growth effect, or 
Eagle effect, described for Candida (51,52), 
which consists of an in vivo attenuation of 
growth inhibition at drug concentrations above 
the inhibitory concentration. The result is growth 
inhibition followed by a resumption of growth at 
higher antifungal concentrations and a new 
inhibitory effect when the drug concentration 
increases. This phenomenon has been associated 
with compensatory mechanisms from the cell 
integrity and calcineurin pathways. In our case, 
the effect was observed in the GS activity in 
vitro, and therefore it cannot be explained in 
terms of cell compensatory mechanisms. In 
addition, the GS activity did not increase but 
remained constant over a broad concentration 
range of antifungal until a new inhibition 
appeared. 
All the mutants selected as resistant to 
echinocandins have been described as dominant 
or semi-dominant (12,20,33,34,36,37,53). Only 
mutants isolated as resistant to papulacandin 
have shown a recessive trait (25). S. cerevisiae 
pbr1-1 resistance is suppressed by the PBR1 / 
FKS1 gene. However, although S. pombe pbr1-8 
resistance was clearly recessive and caused by a 
bgs4+ mutation, bgs4+ expressed from plasmids 
was unable to suppress it. Our studies show that 
chromosomal and plasmid expression may differ, 
at least in their resulting phenotype; a recessive 
chromosomal trait can appear as dominant when 
the complementing gene is expressed ectopically. 
However, the complementing gene remains 
dominant over the recessive allele when both are 
expressed ectopically or when the chromosomal 
recessive gene dosage decreases, as is the case of 
hemi-dosage diploid cells. This explains the 
ability of bgs4+ plasmids to suppress -in pbr1-8 
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cells- the low resistance to caspofungin, but not 
higher resistances to the other inhibitors. These 
results show that in some cases typical gene 
cloning by suppression of the recessive mutant 
phenotype may not be possible and hence other 
techniques must be used. 
All the echinocandin resistance mutations 
have been localized in a 9-amino-acid resistance 
hot spot 1. In this work, we found interesting 
new mutations that conferred resistance to the 
three antifungal families and were external to the 
hot spot 1. One of these mutations extends the 
hot spot to 13 amino acids in the resistance hot 
spot 1-1. The other mutation, although in the 
same region, is distant and defines a new 
resistance hot spot 1-2. The use of other GS-
specific drugs, such as papulacandin, and the use 
of other species, such as S. pombe, have been 
shown to be helpful to define new amino acids 
and regions in GS that are important for 
interaction with antifungals. Studying these and 
other new resistances will help to develop more 
efficient antifungals, such as caspofungin, which 
is able to inhibit resistant mutants at 
concentrations closer to those effective for wild-
type cells. 
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The abbreviations used are: GS, β(1,3)glucan synthase; MIC, minimal inhibitory concentration; IC50, 
half-maximal inhibitory concentration. 
 
FIGURE LEGENDS 
 
Fig. 1. Morphology of pbr1-8 and pbr1-6 cells. (A) Normal and lemon shaped morphology of 
pbr1-8 and bgs4Δ bgs4pbr1-8 cells and rounded morphology of pbr1-6 and bgs4Δ bgs4pbr1-6 cells. 
Osmotic stabilization with sorbitol (S) suppresses the pbr1-6 rounded morphology, after which a 
multiseptated phenotype appears. Phase-contrast and Calcofluor white-stained (50 μg/ml) micrographs 
of early log-phase cells grown on YES medium at 28 °C. Bar, 10 μm. (B) Spherical morphology of 
original pbr1-6 strain (W760S substitution) and elongated cell-shape of a spontaneous pbr1-6 
morphological revertant (W760S and A914V changes) and of a bgs4Δ bgs4pbr1-6 (W760S A914V) strain. The 
pbr1-6 resistance is not affected with the A914V suppressor mutation (Table 3).  
 
Fig. 2. Chemical structures of the three families of specific β(1,3)glucan synthase inhibitors. 
Structures of the inhibitors representative of each family used in this work: papulacandin B 
(papulacandins), enfumafungin (acidic terpenoids), aculeacin A, pneumocandin B0 and caspofungin 
(echinocandins).  
 
Fig. 3. Differential effect of papulacandin B and enfumafungin and of pneumocandin B0, 
aculeacin A and caspofungin on the cell growth of the wild-type, pbr1-8, and pbr1-6 strains. Early 
log-phase cells were grown in YES medium at 28ºC either in the absence or in the presence of the 
indicated antifungal concentrations. Cell growth was monitored at the indicated times. (A) 
papulacandin and enfumafungin produce total cell growth arrest in wild-type cells whereas pbr1-8 
cells are completely resistant. However, echinocandins permit a residual growth of wild-type cells and 
produce slow cell growth in pbr1-8 cells. (B) pbr1-6 cells are resistant to only some antifungals; very 
resistant to papulacandin; partially resistant to pneumocandin, and sensitive to aculeacin. pbr1-6 cells 
are also resistant to enfumafungin and caspofungin (see Tables 2 and 3). Pap, papulacandin. Enf, 
enfumafungin. Pne, pneumocandin. Acu, aculeacin. Csp, caspofungin. 
 
Fig. 4. Differential inhibitory effect of papulacandin B, enfumafungin, pneumocandin B0, 
aculeacin A and caspofungin on the in vitro β(1,3)glucan synthase (GS) activity of wild-type and 
pbr1 cell extracts. (A) Inhibitory effect on the wild-type GS activity. Papulacandin shows an 
inhibitory capacity 103-104-fold higher than the other antifungals, except caspofungin (see Table 2). 
(B) Inhibitory effect on the GS activity of pbr1 cell extracts. pbr1-6 and pbr1-8 GS are highly 
resistant, with IC50 values above 250 μg/ml. The pbr1-6 strain was characterized in vivo as aculeacin 
A-sensitive but its in vitro GS activity was partially resistant. (C) Inhibitory effect of caspofungin on 
the wild-type GS activity. Caspofungin exhibits a very high inhibitory capacity: 102-103-fold higher 
than other antifungals, except papulacandin (see Table 2). Caspofungin shows a dual inhibitory effect, 
at low and high concentrations (first and third sections marked by dotted lines), separated by a plateau 
of a 100-fold drug increase with no increase in inhibition (middle section marked by dotted lines). (D) 
Resistance of pbr1-6 and pbr1-8 GS activities to caspofungin. pbr1-8 GS is totally resistant and pbr1-
6 is partially resistant to the low-concentration inhibitory effect, but both GS are sensitive to the high-
concentration inhibitory effect. Caspofungin is the only antifungal able to produce a noticeable 
inhibition of both mutant GS, with IC50 values below 250 μg/ml. Results are shown as percentages of 
residual GS activity. Error bars show standard deviations. 
 
Fig. 5. The resistance phenotypes of pbr1-6, but not those of pbr1-8, can be suppressed by 
bgs4+ expression. (A) bgs4+ expression cannot suppress the recessive resistances to papulacandin, 
enfumafungin and pneumocandin of pbr1-8. bgs4+ is only able to suppress the caspofungin resistance 
of pbr1-8. Cells were grown and monitored as in fig 3. (B) The recessive pbr1-6 resistances to GS 
antifungals are suppressed by bgs4+ expression (see also Table 3). (C) bgs4+ is unable to suppress the 
in vitro pbr1-8 GS resistance. Extracts of cells transformed with empty or bgs4+ multicopy plasmids 
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were assayed for in vitro GS activity in the presence of 10 μg/ml of papulacandin or 60 μg/ml of 
pneumocandin (concentrations that produce high inhibition of the wild-type GS) as in fig. 4.  
 
Fig. 6. bgs4 is responsible for at least part of the resistance phenotype of pbr1-8 strain. Cells 
were grown and monitored as in fig 3. (A) bgs4 cloned from the pbr1-8 strain confers antifungal 
resistance to a bgs4Δ strain. The bgs4pbr1-8 resistance is recessive in a wild-type (bgs4+) strain. (B) The 
pbr1-8 resistance is recessive in heterozygosis (WT / pbr1-8). However, pbr1-8 confers resistance to 
pbr1-8 / bgs4Δ diploid strains. (C) The pbr1-8 / bgs4Δ resistance phenotype can be suppressed by 
bgs4+ expression. The expression of p81X-bgs4+ suppresses the pbr1-8 / bgs4Δ resistance when the 
81X promoter is induced (- thiamine, -T) and maintains the pbr1-8 / bgs4Δ resistance when the 81X 
promoter is repressed (+ thiamine, +T). 
 
Fig 7. pbr1-6 and pbr1-8 resistances are due to single amino acid substitutions of the Bgs4 
sequence. (A) Hydropathy profile of Bgs4. The two predicted TM regions and the sites where 
Bgs4pbr1-8-E700V and Bgs4pbr1-6-W760S are located in the first TM region are shown. (B) Sequence 
alignment of a conserved region of 70 amino acids of Bgs1, Bgs2, Bgs3 and Bgs4 from S. pombe, 
Fks1 and Fks2 from S. cerevisiae (Sc), Gsc1 (Fks1) from Candida albicans (Ca), and Fks1 and Fks2 
from Candida glabrata (Cg). The amino acid mutations described to confer resistance to 
echinocandins in Sc, Ca and Cg, defining a resistance hot spot 1 of 9 amino acids, are shown. The 
Bgs4pbr1-8 mutation is located 4 amino acids N-terminal from hot spot 1, increasing the cluster to a 13 
amino acid hot spot 1-1 of resistance to papulacandin, enfumafungin and echinocandins. The Bgs4pbr1-6 
change is located 48 amino acids C-terminal from hot spot 1-1, defining a novel hot spot 1-2 of 
resistance to the three antifungal families. 
TABLE 1. Increasing cell wall defects of S. pombe pbr1-8 and pbr1-6 strains. 
 
Strain Alkali extractiona % Lysis of cell suspensionsb % Incorporation of [14C]glucosec Cell wall hexosesd  
 % residual cell wall Novozyme Zymolyase Cell wall β-Glucan α-Glucan Galactomannan Glc Man  Gal 
 
WT 12.7 + 1.6 13.4 + 3.3 71.7 + 3.0 25.4 + 0.3 14.0 + 0.2 7.6 + 0.4 3.8 + 0.3 88.8 + 0.1 7.4 + 0.2 3.7 + 0.2 
pbr1-8 10.9 + 0.6 50.1 + 6.5 60.9 + 2.6 27.7 + 0.7 15.1 + 0.5 9.2 + 0.5 3.4 + 0.1 91.3 + 1.0 5.5 + 0.6 3.2 + 0.3 
pbr1-6   1.8 + 0.2 69.6 + 4.1 44.1 + 3.9 28.2 + 1.0 15.2 + 0.9 11.7 + 0.8 1.3 + 0.2 97.4 + 0.6 1.8 + 0.3 0.7 + 0.2 
 
Values are the means and standard deviations (SD) calculated from at least three independent experiments. 
a Mild alkali extraction of the cell wall (6% NaOH, room temperature, 5 min). Standard alkali extraction removes the entire cell wall. 
b Percentage of OD600 decrease after 6 hours in the presence of Novozyme (10 mg/ml) or Zymolyase (2 mg/ml). Novozyme 234 complex degrades the entire cell wall whereas 
Zymolyase 100T degrades all the cell wall except α-glucan. 
c Percentage incorporation of [14C]glucose into the cell wall polysaccharides (cpm incorporated per fraction x 100 / total cpm incorporated). 
d Percentage of cell wall hexoses analyzed by gas-liquid chromatography. 
Table 2. In vivo Minimal Inhibitory Concentration (MIC) and in vitro half-maximal 
inhibitory concentration (IC50) of wild type, pbr1-8 and pbr1-6 strains. 
 
 
MIC (µg/ml) 
 
Strain Papulacandin Enfumafungin Pneumocandin  Caspofungin 
 
WT 5 10 5 10 
pbr1-8 >100 >100 >100 50 
pbr1-6 >100 >100 50 30 
 
 
 
IC50 (µg/ml) 
 
Strain Papulacandin Enfumafungin Pneumocandin  Caspofungin 
 
WT 0.02 40 120 0.3 
pbr1-8 >250 >250 >250 250 
pbr1-6 >250 >250 >250 150 
 
 
 
 
 
 
 
 
 
 
 
Table 3. bgs4+ plasmids cannot suppress the recessive resistance mutation of the pbr1-8 
strain but are able to suppress that of the pbr1-6 strain. 
 
Strain Papulacandin Enfumafungin Echinocandin  Caspofungin 
 (20 μg/ml) (20 μg/ml) (20 μg/ml) (20 μg/ml) 
 
WT - - - + 
WT (pJK-bgs4pbr1-8) + + + + 
WT pAL-bgs4pbr1-8 + + + + 
pbr1-8 +++ +++ +++ +++ 
pbr1-8 (pJK-bgs4+) +++ +++ ++ + 
pbr1-8 pAL-bgs4+ +++ +++ ++ + 
 
WT / WT - - - - 
pbr1-8 / pbr1-8 +++ +++ +++ +++ 
WT / pbr1-8 + + + - 
WT / WT (pJK-bgs4pbr1-8) - - + - 
WT / WT pAL-bgs4pbr1-8 + - + - 
pbr1-8 / pbr1-8 (pJK-bgs4+) +++ +++ +++ + 
pbr1-8 / pbr1-8 pAL-bgs4+ +++ +++ +++ + 
 
pbr1-6 (W760S) +++ +++ +++ ++ 
pbr1-6 (W760S A914V) +++ +++ +++ ++ 
pbr1-6 / pbr1-6 +++ +++ +++ +++ 
WT / pbr1-6 - - - - 
WT (pJK-bgs4pbr1-6) + + + - 
WT pAL-bgs4pbr1-6 + + + - 
pbr1-6 (pJK-bgs4+) + + + + 
pbr1-6 pAL-bgs4+ + + + + 
 
(pJK-bgs4+): single copy integrative plasmid; pAL-bgs4+: multicopy plasmid. 
The pbr1-6 (W760S A914V) strain contains the spontaneous A914V substitution that suppresses the 
spherical morphology but maintains the resistance phenotype of pbr1-6 (W760S) strain. 
-: no growth; +++: total growth. 
 
 
 
 
 
 
Table 4. The resistances conferred by bgs4pbr1-8 plasmids to a bgs4Δ strain can be 
suppressed by bgs4+ plasmids. 
 
Strain Papulacandin Enfumafungin Echinocandin    Caspofungin 
 (20 μg/ml) (20 μg/ml) (20 μg/ml) (20 μg/ml) 
 
bgs4Δ S4 - - - + 
bgs4Δ SH - - - + 
bgs4Δ R4 +++ +++ +++ ++ 
bgs4Δ RH +++ +++ +++ ++ 
bgs4Δ S4 SH - - - + 
bgs4Δ R4 RH +++ +++ +++ +++ 
bgs4Δ S4 RH - - - - 
bgs4Δ R4 SH + + - - 
bgs4Δ S4 / bgs4Δ SH - - - - 
bgs4Δ R4 / bgs4Δ RH +++ +++ +++ +++ 
bgs4Δ S4 / bgs4Δ RH - - - - 
bgs4Δ R4 / bgs4Δ SH - - - - 
 
S4: pJK-bgs4+ inserted into the bgs4+ promoter. 
R4: pJK-bgs4pbr1-8 inserted into the bgs4+ promoter. 
SH: phis3-bgs4+ inserted into the his3+ promoter. 
RH: phis3-bgs4pbr1-8 inserted into the his3+ promoter. 
-: no growth; +++: total growth. 
 
 
 
Table 5. Suppression of pbr1-8 resistances by regulatable bgs4+ expression plasmid and of 
hemi-dosage pbr1-8 / bgs4Δ diploid resistances by bgs4+ plasmids (own promoter) suggests 
a dosage-dependent suppression (compare with Table 3). 
 
Strain Papulacandin Enfumafungin Echinocandin Caspofungin 
 (20 μg/ml) (20 μg/ml) (20 μg/ml) (20 μg/ml) 
 
WT p81X-bgs4pbr1-8  -T (on) - - - - 
WT p81X-bgs4pbr1-8  +T (off) - - - - 
pbr1-8 p81X-bgs4+  -T (on) - + + - 
pbr1-8 p81X-bgs4+  +T (off) +++ +++ +++ ++ 
 
WT / WT p81X-bgs4pbr1-8  -T (on) - - - - 
WT / WT p81X-bgs4pbr1-8  +T (off) - - - - 
pbr1-8 / pbr1-8 p81X-bgs4+  -T (on) - + - + 
pbr1-8 / pbr1-8 p81X-bgs4+  +T (off) +++ +++ +++ ++ 
 
WT / bgs4Δ - - - - 
pbr1-8 / bgs4Δ +++ +++ +++ +++ 
WT / bgs4Δ (pJK-bgs4pbr1-8) + + + + 
WT / bgs4Δ pAL-bgs4pbr1-8 + + - - 
pbr1-8 / bgs4Δ (pJK-bgs4+) + + + + 
pbr1-8 / bgs4Δ pAL-bgs4+ + + - - 
 
p81X-bgs4+: multicopy plasmid with the 81X version of the thiamine repressible nmt1+ promoter. 
-T: absence of thiamine, induced conditions (on). +T: presence of thiamine, repressed conditions (off). 
(pJK-bgs4+): single copy integrative plasmid; pAL-bgs4+: multicopy plasmid. 
-: no growth; +++: total growth. 
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Bgs4 amino acid number
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A
B
Bgs4p 696 CKFAESYFFLTLSIRDPIIVLSTMRPYLCSIYWAGSRLCFVQPRIILGIMYFTDLILFFLDTYLWYIIFN 765
Bgs1p 515 AKFLESYFFLTLNLADSIRFLGAMRPYDCRDYILGAGLCKAQPKILLSLLYLTDLSLFFLDTYLWYILIS 584
Bgs2p 666 AKFTESYFFLSLSFRDPILVLSTMKPYLCNITFLGSHLCIWQPKILLGIMYVTDLVLFFLDTYLWYILVN 735
Bgs3p 606 AKFVESYYFLTLSVRDPIRFLQRMKPYDCYDFMIGASLCSHQPKFLLSLVYLTDLVLFFLDTYLWYMLIS 675
Sc Fks1p 631 AKYSESYYFLVLSLRDPIRILSTTAMRCTGEYWWGAVLCKVQPKIVLGLVIATDFILFFLDTYLWYIIVN 700
Sc Fks2p 650 AKYAESYFFLILSLRDPIRILSTTSMRCTGEYWWGNKICKVQPKIVLGLMIATDFILFFLDTYLWYIVVN 719
Ca Gsc1p 633 AKLVESYFFSTLSLRDPIRNLSTMTMRCVGEVWYKDIVCRNQAKIVLGLMYLVDLLLFFLDTYMWYIICN 702
Cg Fks1p 617 AKYAESYYFLILSLRDPIRILSTTTMRCTGEYWWGSKLCRHQSKIVLGLMIATDFILFFLDTYLWYIVVN 686
Cg Fks2p 651 AKYSESYFFLILSLRDPIRILSTTTMRCTGEYWWGSKLCRHQSKIVLGFMIATDFILFFLDTYLWYIVVN 720
.*  ***:*  *.. *:*  *                :*  *.:::*.::  .*: *******:**:: .
Bgs4pbr1-8 - E700V
Sc Fks2-1 - I660K
Bgs4pbr1-6 - W760S
Sc Fks1 - L642S
Ca Gsc1 - L644F
RESISTANCE HOT SPOT 1-2
Ca Gsc1 - S645P,Y,F,C
Cg Fks1 - S629P
Cg Fks2 - S663P
Sc Fks1-3 - D646Y
Ca Gsc1 - D648Y
Cg Fks1 - D632G,E,Y
Cg Fks2 - D666G,E
Ca Gsc1 - P649H
Cg Fks2 - P667T
Sc Fks1-2 - F639I
Ca Gsc1 - F641S,Y,L
Cg Fks1 - F625S
Cg Fks2 - F659S,V
RESISTANCE HOT SPOT 1-1
